POSC321 Estimating Long-Term Survivorship Rates for Previously Untreated Intermediate or Poor (I/P) Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI): Analyses from the CheckMate 214 Trial

V Paly,S George,Jh Youn,J Borrill,F Ejzykowicz,Jr May,M Kurt

doi:10.1016/j.jval.2021.11.1025

POSC321 Estimating Long-Term Survivorship Rates for Previously Untreated Intermediate or Poor (I/P) Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI): Analyses from the CheckMate 214 Trial

V Paly, S George + Show 5 more

Open Access

https://doi.org/10.1016/j.jval.2021.11.1025

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jan 1, 2022
Citations: 1	License type: elsevier-specific: oa user license

Affiliation: Roswell Park Cancer Institute, Imperial Consultants, Bristol-Myers Squibb (United Kingdom), Bristol-Myers Squibb (United States)

#Mixture Cure Models #Nivolumab Plus + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

This analysis aimed to explore survival heterogeneity and estimate proportion of potential long-term survivors (LTS) among previously untreated, I/P risk aRCC patients who received immune-checkpoint inhibitors (ICIs) NIVO+IPI in the CheckMate 214 trial by applying mixture cure models (MCMs).

Full Text